CD8A and familial pancreatic carcinoma: In the beginning, anti-CAFs-DMS-AptT might not be able to bring CD8+ T lymphocytes into pancreatic tumor tissues, nevertheless, antiCAFs-DMS-AptT can still deliver AG17724 into CAFs and thus disrupt the immunosuppressive TME of pancreatic cancer, rendering it “reachable” and “reactive” by immune cells.